
BioSpace
BioSpaceAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 20 minutes
- Latest episode:
About this show
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Covers: biopharma industry, drug development, fda regulation, pharmaceutical business, clinical trials, cell and gene therapy, oncology, biotech funding, drug shortages, job market
Show details and episodes come from the publisher's public feed at api.riverside.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
BioSpace is a podcast about the business of biopharma and science, covering layoffs, pipeline changes, acquisitions, FDA approvals and how AI might be regulated in drug development. Recent episodes cover drug shortages, Novartis's Zolgensma tumor reports, intratumoral cancer therapies, and kidney disease drug development.
Cosmos
Similar in subject
- On The Pen GLP-1 News
Both cover: drug shortages, pharmaceutical business, clinical trials - Cell & Gene: The Podcast
Both cover: cell and gene therapy, biopharma industry, drug development - The Top Line
Both cover: biopharma industry, drug development, clinical trials
Similar shows
Explore more
Episodes
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
· 20 min
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.
Not rated yetBreaking borders: Building biotech scale in Benelux
· 18 min
In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We examine why Benelux delivers world‑class science yet remains an investment patchwork, and what it will take to knit the region into a truly unified biotech investment corridor. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Christina Takke (https://www.linkedin.com/in/christina-takke-a93200/), Managing Partner, V-Bio Ventures Mariette van der Velden-Roesink (https://www.linkedin.com/in/mlroesink/), Founding Partner, Curie Capital Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetNovartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
· 20 min
Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking pancreatic cancer drug; BioNTech suspends a mid-stage trial of its mRNA cancer immunotherapy after a futility analysis; and nine mid-sized biopharma companies join their big pharma peers in President Donald Trump’s Most Favored Nation drug pricing scheme.
Not rated yetFragile X at a turning point: Breaking through the clinical bottleneck
· 19 min
In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Hilary Rosselot (https://www.linkedin.com/in/hilary-rosselot/), Executive Director, National Fragile X Foundation Jordi Fàbrega (https://www.linkedin.com/in/fabregajordi/), Co-Founder & CEO, CONNECTA Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetCapricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
· 23 min
FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for their mRNA-based cancer vaccine; Trump nominates White House aide Heidi Overton as FDA commissioner; and the oral obesity market heats up with rivals Eli Lilly and Novo Nordisk going head-to-head.
Not rated yetRewriting the rules of CMV prevention
· 19 min
In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at Oxford University. We explore transplantation and antiviral innovation and why CMV remains one of the most persistent and consequential challenges facing transplant patients today. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Ian McGowan (https://www.linkedin.com/in/ian-mcgowan-3270805/), CMO, Synklino James Hunter, Associate Professor of Transplantation, Oxford University Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. Custom Fields
Not rated yetAmylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
· 19 min
Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.
Not rated yetThe Italian inflection point: Clinical strength, culture and capital
· 18 min
In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at Angelini Ventures. We explore how Italy’s life sciences ecosystem has evolved over the last decade—from stronger tech transfer and growing venture capital to the gaps that still keep it from matching the UK, Germany or France in company creation and scale. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Diana Saraceni (https://www.linkedin.com/in/diana-saraceni-74994/), Founder and Managing Partner, Panakès Partners Fabrizio Calisti (https://www.linkedin.com/in/fabrizio-calisti-26109263/), Medical Director, Angelini Ventures Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetReplimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
· 19 min
After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.
Not rated yetRumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
· 23 min
The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.
Not rated yetThe next treatment-resistant depression paradigm
· 20 min
In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Hans Eriksson, (https://www.linkedin.com/in/hansaeriksson/) Chief Medical Officer, FundaMental Pharma Steve Levine (https://www.linkedin.com/in/steve-levine-md-43908a12/), Chief Patient Officer, Compass Pathways Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetLife after the lead asset: Advancing an early-stage pipeline
· 24 min
In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively. This episode is presented in partnership with Arvinas (https://www.arvinas.com/). Host Jennifer Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guest Randy Teel (https://www.linkedin.com/in/randyteel/), President and CEO, Arvinas
Not rated yetCapricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
· 17 min
The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.
Not rated yetNordic biotech’s next act: From fragmentation to global force
· 20 min
In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Ester Sklarsky (https://www.linkedin.com/in/estersklarsky/), Principal, Sound Bioventures João Ribas (https://www.linkedin.com/in/joaoribas/), Partner, Novo Holdings Seed Investments Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetQ2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
· 21 min
Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.
Not rated yetThe future of pain relief: Exploring opioid alternatives
· 19 min
In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Lance Alstodt (https://www.linkedin.com/in/lance-alstodt-b9951315/), Chairman & CEO, BioRestorative Therapies Paul Mieyal, (https://www.linkedin.com/in/paul-mieyal/)Chief Business Officer, South Rampart Pharma Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetBiogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
· 21 min
Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.
Not rated yetBonus: Q2 2026 Job Market Update
· 9 min
In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.
Not rated yetFrom sequence to scale: Gene editing’s new era in biologics manufacturing
· 20 min
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP. Host Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace Guests Jack Crawford (https://www.linkedin.com/in/jackcrawford1/), CEO, Demeetra Magnus Gustafsson (https://www.linkedin.com/in/magnus-gustafsson-6071a74/), Chief Commercial Officer, NorthX Biologics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Not rated yetVertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
· 17 min
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.
Not rated yet